Seeking to deliver the “final nail in the coffin for HIV,” NIH scientists have kicked off a large clinical trial of a vaccine regimen this week in South Africa.
Under a collaboration that includes GlaxoSmithKline and Sanofi Pasteur, the National Institute of Allergy and Infectious Diseases started a phase 2b/3 trial of a new vaccine regimen in 5,400 sexually active men and women aged 18 to 35 who don’t have the infection. They’ll receive five injections over a year.
{iframe}http://www.fiercepharma.com/vaccines/nih-others-launch-historic-hiv-trial-vaccines-from-gsk-sanofi{/iframe}